Sustained hepatic and systemic inflammation, in particular originating from monocyte/macrophages, is a driving force for chronic liver disease […]

The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IPF. The inventors showed that EPAC1 […]

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, […]

The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. In particular, the […]

CB1 were highly induced in human cirrhotic samples and in liver fibrogenic cells. Treatment with specific CB1 antagonist decreased the wound-healing […]